

## An aberrant case of rapidly progressing lung adenocarcinoma in a Ukrainian refugee

Agnieszka Styczeń<sup>1</sup>, Martyna Janczewska<sup>1</sup>, Joanna Kurzepa<sup>2</sup>, Andrzej Tomaszewski<sup>1</sup>, Michał Tomaszewski<sup>1</sup>

<sup>1</sup>Department of Cardiology, Medical University of Lublin, Lublin, Poland

<sup>2</sup>Department of Medical Radiology, Medical University of Lublin, Lublin, Poland

**Correspondence to:**

Martyna Janczewska, MD,  
Department of Cardiology,  
Medical University of Lublin,  
Jaczewskiego 8, 20–954 Lublin,  
Poland

phone: +48 81 724 42 26,  
e-mail:

m.janczewska2002@gmail.com

Copyright by the Author(s), 2023

DOI: 10.33963/v.kp.97151

**Received:**

July 18, 2023

**Accepted:**

August 28, 2023

**Early publication date:**


September 3, 2023

A 65-year-old Ukrainian female refugee with a low-differentiated adenocarcinoma of the right (R) lung (diagnosed 1.5 years earlier) reported to the Emergency Department with shortness of breath, fever, and a wet cough. A thoracotomy was performed during her previous hospitalization in Ukraine. Microscopic examination, performed at that time, confirmed low- low-differentiated G3 lung adenocarcinoma, and immunogenetic tests detected the ALK+ tyrosine kinase gene rearrangements. The patient had received several courses of treatment with ALK inhibitors — crizotinib and alectinib. Due to cancer progression, therapy with another ALK blocker, brigatinib, had been initiated in the third line. On admission to the Department of Pulmonology and Oncology, physical examination showed tachycardia, tachypnoea and a decrease in the alveolar murmur over the R lung and the upper parts of the left lung. Laboratory test results initially revealed significantly elevated markers of inflammation (leukocytosis with the left shift: leukocytes — 60750 cells/ $\mu$ l, neutrophils — 58660 cells/ $\mu$ l), elevated C-reactive protein (218 mg/l, upper limit of normal = 5 mg/l), and procalcitonin (4.72 ng/ml, upper limit of normal <5 ng/ml). Chest computed tomography angiography showed that the R lung was practically completely airless (Figure 1A) and there was a pathological nodular lesion in the R lung (adjacent to the bifurcation of the pulmonary trunk, surrounding the branches of the R pulmonary artery, infiltrating the R upper lobe artery, segmental arteries to the 3R segment and peripheral branches of the subsegmental arteries to the R middle lobe) obstructing the bronchi of the R lung (Figure 1B). We observed the impression of the nodular mass on the

superior vena cava and the R atrium. A pathological soft-tissue mass was visualized in the lumen of the left atrium (LA) of approximately 63 × 32 mm (right-left × anterior-posterior), protruding through the mitral valve into the left ventricle (Figure 1B), compressing the left ventricular outflow tract (LVOT) and the aortic valve. Massive mediastinal, cervical, and supraclavicular lymphadenopathy and pathological effusion in both pleural cavities and in the pericardium were found. Right-sided pneumonia was diagnosed, secondary to the underlying disease, and broad-spectrum intravenous empirical antibiotic therapy (amoxicillin + clavulanate, ciprofloxacin) improved the patient's condition.

Transthoracic echocardiography revealed a tumor filling almost the entire LA (Figure 1C–E), originating from the R superior pulmonary vein. Four-chamber view (color Doppler) showed stenotic mitral flow (Figure 1F). The disease was identified as T4N3M1 stage IV. The patient was disqualified from cardiac surgery by the Heart Team due to the very advanced stage of cancer. Brigatinib treatment was continued. She was discharged for further outpatient care and died a month later.

Lung adenocarcinoma with ALK gene rearrangement is a specific molecular subtype of lung adenocarcinoma [1] characterized by a high ability to give rise to distant metastases, including heart cavities. Mechanisms by which LA involvement occurs may be direct invasion by the primary tumor, involvement of lymph nodes, or, the least common, pulmonary venous transfer of the original lesion [2]. The condition requires surgery, which, however, may involve the risk of neoplastic dissemination, hemorrhage, and a higher probability



**Figure 1.** **A.** Axial projection of CT in the arterial phase. Extensive mass located in the right lung filling almost the entire left atrial cavity. A small amount of fluid in both pleural cavities. **B.** CT, 3D volume rendering presenting nodular masses in the mediastinum and the right lung, poor vascularization of the right lung, and a nodule mass passing from the LA to the LV. **C.** TTE, parasternal long axis view, tumor mass visible in the LA (arrows). **D.** TEE, aortic valve level, tumor visible in the right lung and the LA. **E.** TTE, apical 4-chamber (A4C) view, pathological soft-tissue mass visualized in the LA (6.5 cm × 2.8 cm), protruding through the mitral valve into the LV. **F.** TTE, Apical 4-chamber view, color Doppler, stenotic mitral flow due to the mass protruding into the LV

Abbreviations: CT, computed tomography; LA, left atrium; LV, left ventricle; LVOT, left ventricular outflow tract; RA, right atrium; RV, right ventricle; TTE, transthoracic echocardiography; TEE, transesophageal echocardiography; TU, tumor

of infection [3, 4]. The decision on the best therapeutic approach should be made by a multidisciplinary team, regarding especially life expectancy. Lung cancer resection can be performed simultaneously with cardiac surgery, but in advanced cases, heart surgery takes precedence over that of the lung [5]. If cardiac surgery is not possible, conservative preparatory treatment with highly selective ALK inhibitors such as alectinib, crizotinib, and brigatinib is recommended.

### Article information

**Conflict of interest:** None declared.

**Funding:** None.

**Open access:** This article is available in open access under Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, which allows downloading and sharing articles with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at [kardiologiapolska@ptkardio.pl](mailto:kardiologiapolska@ptkardio.pl).

### REFERENCES

1. Bi R, Bai Q, Zhu X, et al. ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma. *Diagn Pathol.* 2019; 14(1):96, doi: [10.1186/s13000-019-0864-7](https://doi.org/10.1186/s13000-019-0864-7), indexed in Pubmed: 31455365.
2. Toyooka S, Mori H, Kiura K, et al. Induction chemoradiotherapy prior to surgery for non-small cell lung cancer invading the left atrium. *Eur J Cardiothorac Surg.* 2008; 33(2): 315–316, doi: [10.1016/j.ejcts.2007.10.022](https://doi.org/10.1016/j.ejcts.2007.10.022), indexed in Pubmed: 18061468.
3. Ratto GB, Costa R, Vassallo G, et al. Twelve-year experience with left atrial resection in the treatment of non-small cell lung cancer. *Ann Thorac Surg.* 2004; 78(1): 234–237, doi: [10.1016/j.athoracsur.2004.01.023](https://doi.org/10.1016/j.athoracsur.2004.01.023), indexed in Pubmed: 15223435.
4. Baron O, Jouan J, Sagan C, et al. Resection of bronchopulmonary cancers invading the left atrium—benefit of cardiopulmonary bypass. *Thorac Cardiovasc Surg.* 2003; 51(3): 159–161, doi: [10.1055/s-2003-40316](https://doi.org/10.1055/s-2003-40316), indexed in Pubmed: 12833206.
5. Płońska-Gościński E, Piotrowski G, Wojakowski W, et al. Management of valvular heart disease in patients with cancer: Multidisciplinary team, cancer-therapy related cardiotoxicity, diagnosis, transcatheter intervention, and cardiac surgery. Expert opinion of the Association on Valvular Heart Disease, Association of Cardiovascular Interventions, and Working Group on Cardiac Surgery of the Polish Cardiac Society. *Kardiol Pol.* 2023; 81(1): 82–101, doi: [10.33963/KP.a2023.0023](https://doi.org/10.33963/KP.a2023.0023), indexed in Pubmed: 36641646.